NCT04544956 - A Mechanistic Study of GSK3228836 With Fine Needle Aspiration (FNA) in Participants With Chronic Hepatitis B | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 6, 2020

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2023

Conditions

Hepatitis B

Interventions

DRUG

GSK3228836

GSK3228836 will be available as a clear colorless to slightly yellow solution for injection in 150 mg/milliliters (mL) vial to be administered SC once weekly.

DRUG

Nucleos(t)ide therapy

Participants receiving nucleos(t)ide therapy upon entry in the study will continue to receive nucleos(t)ide therapy for the duration of the study.

Trial Locations (4)

02114

GSK Investigational Site, Boston

M5G 2C4

GSK Investigational Site, Toronto

3015 GD

GSK Investigational Site, Rotterdam

E1 1BB

GSK Investigational Site, London